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Abstract
Introduction: Early systemic sclerosis (SSc) is characterized by Raynaud’s phenomenon together with scleroderma
marker autoantibodies and/or a scleroderma pattern at capillaroscopy and no other distinctive feature of SSc.
Patients presenting with marker autoantibodies plus a capillaroscopic scleroderma pattern seem to evolve into
definite SSc more frequently than patients with either feature. Whether early SSc patients with only marker
autoantibodies or capillaroscopic positivity differ in any aspect at presentation is unclear.
Methods: Seventy-one consecutive early SSc patients were investigated for preclinical cardiopulmonary alterations.
Out of these, 44 patients and 25 controls affected by osteoarthritis or primary fibromyalgia syndrome were also
investigated for serum markers of fibroblast (carboxyterminal propeptide of collagen I), endothelial (soluble
E-selectin) and T-cell (soluble IL-2 receptor alpha) activation.
Results: Thirty-two of the 71 patients (45.1%) had both a marker autoantibody and a capillaroscopic scleroderma
pattern (subset 1), 16 patients (22.5%) had only a marker autoantibody (subset 2), and 23 patients (32.4%) had only
a capillaroscopic scleroderma pattern (subset 3). Patients with marker autoantibodies (n = 48, 67.6%) had a higher
prevalence of impaired diffusing lung capacity for carbon monoxide (P = 0.0217) and increased serum levels of
carboxyterminal propeptide of collagen I (P = 0.0037), regardless of capillaroscopic alterations. Patients with a
capillaroscopic scleroderma pattern (n = 55, 77.5%) had a higher prevalence of puffy fingers (P = 0.0001) and
increased serum levels of soluble E-selectin (P = 0.0003) regardless of marker autoantibodies.
Conclusion: These results suggest that the autoantibody and microvascular patterns in early SSc may each be
related to different clinical-preclinical features and circulating activation markers at presentation. Longitudinal
studies are warranted to investigate whether these subsets undergo a different disease course over time.
Keywords: Raynaud’s phenomenon, early systemic sclerosis, systemic sclerosis marker autoantibodies, nailfold
videocapillaroscopy, preclinical organ involvement, puffy fingerscirculating activation markers, carboxyterminal
propeptide of collagen I, soluble E-selectin, soluble IL-2 receptor alpha
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Introduction
Early systemic sclerosis (SSc) is a condition characterized
by Raynaud’s phenomenon (RP) associated with SSc mar-
ker autoantibodies (anti-Scl-70, anticentromere antibodies,
anti-RNA polymerase III, anti-fibrillarin, anti-PmScl, and
anti-Th/To) and/or nailfold videocapillaroscopy (NVC)
findings typical of SSc (namely, megacapillaries and avas-
cular areas - commonly referred to as an ‘NVC sclero-
derma pattern’). By definition, patients with early SSc do
not show any distinctive clinical manifestation of the dis-
ease (namely, sclerodactyly, digital ulcers/scars, two or
more teleangectasias, clinically visible nailfold capillaries,
cutaneous calcinosis, X-ray bibasilar lung fibrosis, X-ray
esophageal dysmotility, electrocardiographic signs of myo-
cardial fibrosis, or a serum creatinine increase suggestive
of scleroderma renal crisis) except puffy fingers and/or
arthritis [1-4].
Various attempts have been made to find a correct clas-
sification for these patients who do not meet the prelimin-
ary 1990 American College of Rheumatology (ACR) SSc
criteria [5] in order to foster their inclusion in clinical
trials. In fact, in 2001 LeRoy and Medsger proposed that
RP patients with SSc marker autoantibodies or an NVC
scleroderma pattern should be classified as being affected
by limited SSc [1]. Seven years later, Koenig and colleagues
validated the LeRoy and Medsger criteria in a large
20-year prospective study [2]. They found that, at the last
follow-up, patients presenting with SSc marker autoanti-
bodies and a scleroderma pattern at capillaroscopy
(referred to as subset 1 in the present paper), with no
other manifestation distinctive of the disease other than
puffy fingers and/or arthritis, had developed definite SSc
60 times more frequently than patients presenting with
only RP. Patients with either only SSc marker autoantibo-
dies (subset 2) or a capillaroscopic scleroderma pattern
(subset 3) had developed definite SSc five and eight times
more frequently, respectively, than patients presenting
with only RP. Koenig and colleagues therefore suggested
that such cases be labeled collectively as early SSc.
Two years ago, we reported that 42% of thus defined
early SSc patients admitted to our tertiary Rheumatology
Unit had preclinical functional alterations of the esopha-
gus, lung or heart [3]. Subsequently, we showed that a
high percentage of early SSc patients develop definite SSc
within 5 years of presentation and found that some circu-
lating fibroblast, endothelial and T-cell activation markers
could be used as predictors of disease evolution besides
marker autoantibodies and NVC findings [4]. In their
study, Koenig and colleagues did not systematically inves-
tigate visceral involvement and neither did they consider
circulating activation markers [2]. In our previous papers
we were unable to try any subsetting among our early SSc
patients because of the low number of early SSc patients
with only an NVC scleroderma pattern and negative for
SSc marker autoantibodies admitted to our unit [3,4].
In the present study, we evaluated whether clinical,
preclinical functional or cellular activation markers are
related to distinct early SSc subsets at presentation by
merging our early SSc cohort with that recruited at a
secondary Angiology Unit, where a significant number




Patients admitted for evaluation of RP from 1 November
2000 to 30 June 2012 to the outpatient clinic of the
Rheumatology Unit of the Second University of Naples
and from 1 January 2008 to 30 June 2012 to the outpati-
ent clinic of the Angiology Unit of the Pertini Hospital
in Rome who met the Koenig and colleagues criteria for
early SSc (that is, RP with SSc marker autoantibodies
and/or an NVC scleroderma pattern without any clinical
manifestation of definite SSc) [2] were enrolled in the
study after giving written informed consent.
The diagnosis of RP was confirmed if patients fulfilled
LeRoy and Medsger’s criteria [6]; that is, if a cold chal-
lenge induced bilateral, episodic biphasic or triphasic
(pallor followed by dusky blueness and/or redness) color
changes of fingers. According to standard clinical prac-
tice, and for the purpose of a correct disease classifica-
tion, patients underwent a complete screening workplan.
Routine assessment
Each patient was investigated to identify any feature that
precluded inclusion in the study. In detail, we looked for
the following features: dysphagia, effort dyspnea, and find-
ings consistent with previous scleroderma renal crisis at
history; symmetrical skin sclerosis, digital ulcers/scars, two
or more teleangectasias, clinically visible nailfold capil-
laries, cutaneous calcinosis, and recent-onset accelerated
or malignant arterial hypertension at physical examination;
bibasilar lung fibrosis at chest X-ray scan; esophageal dys-
motility at barium esophageal X-ray scan; and blocks and/
or Q waves at electrocardiography. In addition, blood cell
count, urinalysis, blood urea nitrogen, serum creatinine,
alanine aminotransferase, aspartate aminotransferase, ery-
throsedimentation rate, serum protein electrophoresis
with the evaluation of g-globulin concentration, and serum
C3 and C4 concentration were also evaluated.
Nailfold videocapillaroscopy assessment
NVC was carried out with an optical probe videocapil-
laroscope equipped with a ×200 magnification contact
lens and connected to image analysis software (Video-
cap; DS MediGroup, Milan, Italy). The nailfold of the
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second, third, fourth and fifth fingers was examined
bilaterally in each patient. Four consecutive fields
extending over 1 mm in the middle of the nailfold were
studied per finger. All images of patients from both cen-
ters were stored and reviewed by a physician (MI)
experienced in NVC [3,4,7]. The degree of capillary enlar-
gement (on a scale of 0 to 3) and capillary loss (graded A
to D) were investigated. Megacapillaries (capillary enlarge-
ment ≥2) and/or avascular areas (capillary loss grade ≥C)
were considered a scleroderma pattern [8,9]. Moreover,
since NVC active and late patterns, which are character-
ized by a lower capillary density, have been found to be
associated with more severe disease in SSc patients [10],
we also subdivided patients according to the mean capil-
lary number per millimeter; that is, >9/mm, 9 to 7/mm,
6 to 4/mm, and ≤3/mm.
Autoantibody profile assessment
An autoantibody screening and profiling of sera collected
at the first visit was performed. Antinuclear antibodies and
anticentromere antibodies were searched for by a conven-
tional indirect immunofluorescence assay on HEp2 cells,
using fluorescent human g-globulins as detection antibo-
dies and a serum dilution of 1:160 as the cutoff value
(Astra srl, Pavone Canavese, Italy). Anti-double-stranded
DNA antibodies were also searched for by indirect immu-
nofluorescence on Crithidia Luciliae, using fluorescent
human g-globulins as detection antibodies and a serum
dilution of 1:40 as the cutoff value (Astra srl). Anti-Scl-70,
anti-PmScl, anti-SSA, anti-SSB, anti-Sm, anti-Jo1, and
anti-U1RNP antibodies were identified by commercially
available ELISA kits (Chematil srl, Angri, Italy), using
25 U/ml as the cutoff value. Anti-RNA polymerase III and
anti-fibrillarin antibodies were identified by EliA Varelisa
test (Phadia, Freiburg, Germany), using 150 U/ml as the
cutoff value. Anti Th/To were identified by western blot-
ting (reagents by Arnika srl, Milano, Italy). To avoid a dif-
ferential verification bias, sera were blindly exchanged
between the two centers and only confirmed results were
considered. Each result was confirmed.
Assessment of preclinical internal organ involvement
Patients from both centers underwent B-mode echocar-
diography and lung function study. Echocardiographic
examination was performed as reported elsewhere [11].
The detection of diastolic abnormalities at B-mode echo-
cardiography, indicated by an inverted ratio between early/
(atrial) late ventricular filling velocity (E/A ratio <1), in the
absence of arterial hypertension, coronary artery disease
and other symptoms/signs of cardiac disease, was regarded
as early scleroderma heart involvement [12]. The detection
of a diffusing lung capacity for carbon monoxide (DLCO)
or a forced vital capacity <80% of the predicted values in
the absence of a smoking habit and/or obstructive lung
disease at lung function study was regarded as SSc lung
involvement [13,14]. Moreover, after further informed
consent, patients from the Rheumatology Unit with a
reduced DLCO underwent high-resolution computed
tomography of the chest [15].
Fibroblast, endothelial and T-cell activation markers
Early SSc patients for whom a baseline serum specimen
was available and 25 controls, matched for sex and age
and affected by osteoarthritis or primary fibromyalgia
syndrome, were investigated at the Rheumatology Unit
laboratory for the fibroblast, endothelial and T-cell acti-
vation markers carboxyterminal telopeptide of type I col-
lagen (ICTP), soluble E-selectin (sE-selectin) and soluble
IL-2 receptor alpha (sIL-2Ra), as described previously
[4]. Briefly, sIL-2Ra and sE-selectin concentrations were
measured by a multiplex suspension immunoassay
(expressed as pg/ml), based on the use of spectrally
encoded beads, each coupled with a capture antibody
specific to the analyte of interest, as the solid support and
a biotinylated detection antibody-streptavidine-phycoery-
thrin complex as the reporter system (all reagents were
from Merk Millipore, Billerica, MA, USA) to be read by a
double laser-based fluorimetric instrument (Luminex
200; Luminex Corporation, Austin, TX, USA). The ICTP
concentrations were measured by a conventional compe-
titive radioimmune assay (expressed as µg/l) (UniQ kits;
Orion Diagnostica, Espoo, Finland). We did not measure
the aminoterminal propeptide of type III collagen serum
concentration because in our previous study it did not
differ between early SSc and either undifferentiated con-
nective tissue disease patients or controls at baseline [4].
Based on the autoantibody and capillaroscopic profiles,
early SSc patients were divided into three subsets: subset
1, patients with both SSc marker autoantibody positivity
and an NVC scleroderma pattern; subset 2, patients with
only SSc marker autoantibody positivity; and subset 3,
patients with only an NVC scleroderma pattern.
The study was reviewed and approved by the Azienda
Ospedaliera Universitaria Seconda Università degli Studi
di Napoli Ethics Committee and by the ASL RM/B
Ethics Committee.
Statistical analysis
GraphPad Prism software version 6.0 (GraphPad Software
Inc., San Diego, CA, USA) was used for statistical analysis.
Continuous data were expressed as the mean ± standard
deviation and the median with range, and were compared
by the unpaired Student’s t test or Mann-Whitney U test
as appropriate when two groups were analyzed, and by
one-way analysis of variance or Kruskal-Wallis test as
appropriate when three or more groups were compared.
Valentini et al. Arthritis Research & Therapy 2013, 15:R63
http://arthritis-research.com/content/15/3/R63
Page 3 of 10
Categorical data were analyzed by Fisher’s exact test and
the chi-square test when two or three groups, respectively,
were considered.
Results
Forty-five patients were enrolled at the Rheumatology Unit
of the Second University of Naples and 26 patients at the
Angiology Unit of the Pertini Hospital in Rome. Table 1
presents the main epidemiologic, laboratory and capillaro-
scopic features of the patients enrolled by the Rheumatol-
ogy and Angiology Units. There was no difference between
the two series in terms of age, sex and time interval elapsed
from the onset of RP. However, the prevalence of subset 1
patients was significantly higher (26/45 (57.8%) vs. 6/26
(23.1%), P = 0.0098) and the prevalence of subset 3 patients
significantly lower (3/45 (6.7%) vs. 20/26 (76.9%), P =
0.0001) in the Rheumatology series. Subset 2 patients were
recruited only by the Rheumatology Unit.
By definition, no patient presented any clinical feature of
SSc other than puffy fingers or arthritis. The prevalence of
puffy fingers was significantly higher in both subset 1 and
subset 3 Angiology Unit patients than in the respective
Rheumatology Unit patients (6/6 vs. 4/26, P = 0.004 for
subset 1; 19/20 vs. 1/3, P = 0.04 for subset 3). The preva-
lence of arthritis did not differ statistically between the
two centers (1/26 (3.85%) for Rheumatology Unit patients
vs. 2/6 (33.3%) for Angiology Unit patients, P >0.05 for
subset 1; 0/3 (0%) for Rheumatology Unit patients vs. 2/20
(10%) for Angiology Unit patients, P >0.05 for subset 3).
Because of the low number of subset 3 patients recruited
at the Rheumatology Unit and of subset 1 patients
admitted to the Angiology Unit, in order to increase the
power of the analysis we merged the two series.
Figure 1 shows the prevalence of puffy fingers (Figure 1A)
and arthritis (Figure 1B) in the three subsets. The preva-
lence of puffy fingers was significantly higher in subset 3
patients (20/23, 87%) from the pooled series than in subset
1 (10/32, 31.3%) and subset 2 (2/16, 12.5%) patients (P =
0.0001) (Figure 1A). Thirty out of the 32 (93.75%) patients
across the three subsets with puffy fingers had a positive
NVC, and 25/39 (64.1%) patients without puffy fingers had
a positive NVC (P = 0.0037) (Figure 1C).
The prevalence of functional abnormalities did not
differ between each subset of patients from the two cen-
ters. A forced vital capacity <80% of the predicted value
and an inverted E/A ratio were found only in 2/32
(6.25%) and 1/32 (3.13%) subset 1 patients, respectively,
and in no subset 2 and subset 3 patients. However, an
impaired DLCO was more prevalent in subset 1 (11/32,
34.4%) and subset 2 (6/16, 37.5%) patients than in sub-
set 3 (2/23, 8.7%) patients (P = 0.057) (Figure 2A). In
addition, out of the 48 marker autoantibody-positive
patients (that is, subset 1 + subset 2), DLCO <80% of
the predicted value was detected in 17 (35.4%) versus
2/23 (8.7%) marker autoantibody-negative subset 3
patients (P = 0.0217) (Figure 2B). Lastly, 6/14 (42.9%)
patients with SSc marker autoantibodies other than
anticentromere antibodies (three anti-Scl-70; three anti-
RNA polymerase III) had a reduced DLCO as compared
with 11/34 (34.4%) anticentromere antibody-positive
patients. The difference did not reach statistical signifi-
cance (Figure 2C).
A ground glass opacity involving <5% of inferior lobes
and an interlobular septal thickening were found in two
patients and two different patients, respectively, by lung
high-resolution computed tomography.
Table 1 Epidemiologic, laboratory and capillaroscopic features of the two early systemic sclerosis series
Feature Rheumatology Unit (n = 45) Angiology Unit (n = 26) P value
Sex (female/male ratio) 43/2 22/4 NS
Age (years) 41 (17-73) 37.5 (16-71) NS
RP duration (years) 3 (0.5-24) 3 (1-20) NS
Subset 1: antibody-positive, NVC-positive 26 (57.8) 6 (2.2) 0.0098
Anti-Scl-70 antibody-positive 5 (19.2) 0
ACA-positive 19 (73.1) 3 (50)
Anti-RNA polymerase III antibody-positive 2 (7.7) 3 (50)
Megacapillaries only 21 (80.8) 3 (50)
Avascular areas ± megacapillaries 5 (19.2) 3 (50)
Subset 2: antibody-positive, NVC-negative 16 (35.6) 0 -
AntiScl-70 antibody-positive 4 (25) 0
ACA-positive 12 (75) 0
Anti-RNA polymerase III antibody-positive 0 0
Subset 3: antibody-negative, NVC-positive 3 (6.7) 20 (76.9) 0.0001
Megacapillaries only 3 (100) 20 (100) -
Avascular areas ± megacapillaries 0 0 -
All data expressed as median (range) or number (percentage). ACA, anticentromere antibody; NVC, nailfold videocapillaroscopy; RP, Raynaud’s phenomenon.
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Sera collected at admission were available for 22/45
(48.9%) patients from the Rheumatology Unit and for
22/26 (84.6%) patients from the Angiology Unit. The clini-
cal, serological and NVC features of the 22 Rheumatology
Unit patients reflected the characteristics of the whole ser-
ies of the center (data not shown). Figure 3 shows serum
levels of the investigated activation markers in the three
early SSc subsets and in controls. Two main findings
emerged from this analysis. Firstly, serum concentrations
of ICTP were significantly higher in patients with SSc mar-
ker autoantibodies (median = 4.025 µg/l in subset 1 + sub-
set 2, range 1.883 to 10.53 µg/l) than in subset 3 patients
(median = 2.51 µg/l, range 1.55 to 6.972 µg/l; P = 0.0108)
(Figure 3A). In detail, 4/15 (26.7%) subset 1 patients and 3/
9 (33.3%) subset 2 patients had ICTP levels that exceeded
the 95th percentile (5.05 µg/l) of the values measured in
controls with respect to 2/17 (11.8%) subset 3 patients.
Secondly, levels of sE-selectin were significantly higher
in patients with an NVC scleroderma pattern (median =
1.031 pg/ml in subset 1 + subset 3, range 0.425 to 7.51 pg/
ml) than in subset 2 patients with only SSc marker autoan-
tibodies (median = 0.67 pg/ml, range 0.486 to 1.203 pg/ml;
P = 0.033) (Figure 3B). In detail, sE-selectin levels exceeded
the 95th percentile of the values recorded in controls
(1.709 pg/ml), in 11/17 (64.7%) subset 3 patients, in 2/15
(13.3%) subset 1 patients and in 0/9 subset 2 patients (P =
0.0003). Noteworthy, we found that among all three sub-
sets sE-selectin levels were significantly higher in patients
with puffy fingers than in those without puffy fingers
(2.013 pg/ml, range 0.55 to 7.51 vs. 0.725 pg/ml, range
0.425 to 1.203 pg/ml; P < 0.0001) (Figure 3C). Finally, sIL-


























Figure 1 Prevalence of puffy fingers, arthritis, and nailfold videocapillaroscopy scleroderma pattern in early systemic sclerosis
patients. Prevalence of (A) puffy fingers and (B) arthritis in the 71 early systemic sclerosis (SSc) patients from both centers, divided into three
subsets according to the SSc marker autoantibody status and the nailfold videocapillaroscopy (NVC) pattern: presence of both SSc marker
autoantibodies and NVC scleroderma pattern (subset 1), presence of SSc marker autoantibodies only (subset 2), and presence of NVC
scleroderma pattern only (subset 3). (C) Prevalence of NVC scleroderma pattern in all patients from both centers divided according to the
presence/absence of puffy fingers. Chi-square test was applied for statistical analysis of data reported in (A) and (B); Fisher’s exact test was
applied for statistical analysis of data reported in (C).
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patients (subset 3: median = 24.41 pg/ml, range 0 to 411.2)
than in SSc marker autoantibody-positive patients (subset
1 + subset 2 patients: median = 239.8 pg/ml, range 66.74
to 1,003 pg/ml; P = 0.0015) (Figure 3D). sIL-2Ra levels
were lower than the 5th percentile of control values
(25.7 pg/ml) in 11/17 (64.7%) subset 3 patients but not in
any subset 1 or subset 2 patient (P = 0.0001).
The mean capillary number was >9/mm in 41 patients,
9 to 7/mm in 24 patients and 6 to 4/mm in six patients.
No statistical difference was found among these three
subgroups in the prevalence of each clinical, preclinical
functional and laboratory abnormality investigated (data
not shown). Finally, none of the investigated clinical
(puffy fingers, arthritis), preclinical (DLCO/forced vital
capacity reduction, E/A ratio inversion), or serological
(SSc marker autoantibodies, ICTP, sE-selectin, sIL-2Ra)
parameters was associated with the disease duration, as
evaluated by RP onset.
Discussion
To our knowledge, this is the first study to systematically
explore clinical and preclinical organ involvement and cir-
culating activation markers in early SSc patients subdivided
into three subsets, depending on the presence of both mar-
ker autoantibodies and NVC scleroderma pattern or either
of these features.
Firstly, we found that our early SSc patients, which
were enrolled by two distinct clinical units, were similar
in sex and age distribution and disease duration, but dif-
fered in terms of clinical features and serum levels of

























Figure 2 Prevalence of diffusing lung capacity for carbon monoxide impairment and systemic sclerosis marker autoantibody
positivity. (A) Prevalence of diffusing lung capacity for carbon monoxide (DLCO) impairment (<80% of the predicted value) in the 71 early
systemic sclerosis (SSc) patients from both centers, divided into three subsets according to the SSc marker autoantibody status and the nailfold
videocapillaroscopy (NVC) pattern: presence of both SSc marker autoantibodies and NVC scleroderma pattern (subset 1), presence of SSc marker
autoantibodies only (subset 2), and presence of NVC scleroderma pattern only (subset 3). (B) Prevalence of general SSc marker autoantibody
positivity and (C) prevalence of either anticentromere antibody (ACA) or other SSc marker autoantibody positivity in all patients from both
centers divided according to the presence/absence of DLCO impairment. Chi-square test was applied for statistical analysis of data reported in
(A). Fisher’s exact test was applied for statistical analyses of data reported in (B) and (C). Abs, autoantibodies.
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fibroblast, endothelial, and T-cell activation markers at
presentation.
Given the different target patients of the two units, it is
not surprising that a higher prevalence of SSc marker auto-
antibody-positive patients was enrolled by the Rheumatol-
ogy Unit whereas a higher prevalence of RP patients
presenting with puffy fingers was enrolled by the Angiology
Unit. These differences are in line with results reported in
patients with definite SSc by Walker and colleagues, who
analyzed data entered into the European League Against
Rheumatism (EULAR) Scleroderma Trials and Research
database and found that differences among patients from
various centers depend mainly on the clinical attitude of
the respective medical team [16]. Notwithstanding this pos-
sible center-related recruitment bias, in our study early SSc
patients with marker autoantibodies had a higher preva-
lence of impaired DLCO and higher circulating levels of
ICTP irrespective of an NVC scleroderma pattern (megaca-
pillaries and/or avascular areas). Similarly, early SSc patients
with an NVC scleroderma pattern had a higher prevalence
of puffy fingers and higher circulating levels of E-selectin
irrespective of circulating marker autoantibodies, the two
features being closely related each other. These associations
have never previously been searched for. Moreover, four
out of the 14 Rheumatology Unit patients with DLCO
<80% of the predicted value already presented mild altera-
tions of lung anatomy as detected by high-resolution com-
puted tomography.
In this context, it is noteworthy that an impaired












































ΎΎ *p < 0.05
**p < 0.005
***p < 0.0005
Figure 3 Serum levels of fibroblast, endothelial, and T-cell activation markers. Serum levels of (A) fibroblast (carboxyterminal telopeptide of type
I collagen (ICTP)), (B) endothelial (soluble E-selectin (sE-selectin)), and (D) T-cell (soluble IL-2 receptor alpha (sIL2Raa)) activation markers in 25 controls
affected by ostheoarthritis or fibromyalgia, and 44 early systemic sclerosis (SSc) patients, divided into three subsets according to the SSc marker
autoantibody status and the nailfold videocapillaroscopy (NVC) pattern: presence of both SSc marker autoantibodies and NVC scleroderma pattern
(subset 1), presence of SSc marker autoantibodies only (subset 2), and presence of NVC scleroderma pattern only (subset 3). (C) Serum levels of
sE-selectin in all patients from both centers divided according to the presence/absence of puffy fingers. Kruskal-Wallis test and Mann-Whitney U test
were applied for statistical analysis of data reported in (A), (B), and (D). Mann-Whitney U test was applied for statistical analysis of data reported in (C).
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lung disease [14,17]. Increased ICTP levels have been
reported in SSc patients [18] and suspected SSc patients
(that is, patients not meeting the preliminary 1990 ACR
criteria for SSc) [4]. Moreover, elevated ICTP levels
have been found to correlate with modified Rodnan skin
score and to be associated with a diffuse disease and a
reduced pulmonary function [19]. Given these observa-
tions, it is conceivable that early SSc patients with SSc
marker autoantibodies are at higher risk of developing
fibrotic organ complications.
Puffy fingers and RP are considered the main clinical
features of the undifferentiated connective tissue syn-
drome [20]. sE-selectin, which reflects endothelial activa-
tion, has been reported to be increased in patients with
definite SSc [21]. Our study demonstrates that puffy fin-
gers are detectable in early SSc patients, mainly in those
with an NVC scleroderma pattern and increased sE-
selectin levels. Serum IL-2Ra levels, which reflect the
activation of the adaptive immune response through
T-cell recruitment, have been found to be strongly asso-
ciated with mortality and inversely correlated to disease
duration in SSc patients with diffuse disease [22]. Intrigu-
ingly, we found that sIL-2Ra levels were strikingly lower
in early SSc patients who were marker autoantibody-
negative. This result could indicate a lack of T-cell
recruitment in the peripheral blood of autoantibody-
negative early SSc patients.
Taken together, the results of our study seem to sug-
gest that the major cellular pathways involved in the
pathogenesis of SSc, as evaluated by serum concentra-
tion of relevant activation markers, differ among early
patients at presentation, in relation to autoantibody
and microvascular status. Nevertheless, the asynchro-
nous appearance of autoantibody positivity and capil-
laroscopic alterations has been reported in two recent
papers. First, Englert and colleagues described the case
of one patient in whom anti-Scl-70 positivity, asso-
ciated with fatigue, weight loss and puffy fingers, pre-
dated the appearance of RP and the development of
capillaroscopic abnormalities [23]. Second, Moinzadeh
and colleagues reported the late appearance of serum
autoantibodies in three patients with an NVC sclero-
derma pattern at admission [24]. Whether SSc marker
autoantibody positivity or the presence of an NVC
scleroderma pattern really do identify the dominating
activation of a given cellular pathway at the disease
onset in early SSc patients can only be determined by
investigating circulating and tissue markers of cell acti-
vation contemporaneously.
Our study has some limitations. First, it might be affected
by a differential verification bias because the patients were
examined by clinicians with different medical expertise. To
reduce this possible bias, however, capillaroscopic images
and sera were made anonymous and centralized to the
Rheumatology Unit. Capillaroscopic images were blindly
evaluated by one investigator experienced in NVC (MI);
sera were blindly analyzed in duplicate by one investigator
experienced in immunoassays (SV). Moreover, the clinical
(puffy fingers) and preclinical (DLCO and E/A ratio) para-
meters used to assess both series of patients are well
defined and routinely applied in clinical practice. Second,
given the small number of patients, our conclusions may
be susceptible to be changed by future studies on large
number of patients, such as the ongoing Very Early Diag-
nosis of Systemic Sclerosis (VEDOSS) project [25,26].
In addition, one must underline that using the new ACR/
EULAR classification criteria presented at the ACR 2012
meeting [27,28], a number of our early SSc patients could
already meet the criteria for SSc at presentation. Indeed, in
a post-hoc analysis 10/71 (14.1%) patients met the new
EULAR/ACR classification criteria for SSc and belonged to
subset 1 (that is, patients with both SSc marker autoantibo-
dies and capillaroscopic abnormalities). These patients met
the new criteria because of the presence of puffy fingers
along with SSc marker autoantibodies and the NVC sclero-
derma pattern. However, our major findings - that is, early
SSc patients with SSc marker autoantibody have higher
ICTP levels, regardless of the NVC pattern; and early SSc
patients with an NVC scleroderma pattern have a higher
prevalence of puffy fingers and higher circulating levels of
E-selectin, regardless the autoantibody profile, the two fea-
tures being closely related each other - did not differ signif-
icantly when we excluded these 10 patients from the
analysis (see Additional files 1, 2, 3 and 4).
In conclusion, we found that early SSc patients show
distinct clinical and preclinical features, and distinct circu-
lating markers of cellular activation at presentation,
according to their autoantibody and capillaroscopic status.
Longitudinal large studies are required to verify whether
the pathophysiological (cellular activation markers), func-
tional (DLCO) and clinical (puffy fingers) differences in
early SSc subsets that we detected in a small yet well char-
acterized cohort really do translate into the development
of different disease patterns over time.
Additional material
Additional file 1: Table S1 presenting epidemiologic, laboratory and
capillaroscopic features in patients who did not meet EULAR/ACR
classification criteria, and figure legends for Figures S1, S2, and S3.
Additional file 2: Figure S1 showing the prevalence of puffy fingers,
arthritis and NVC scleroderma pattern in patients who did not meet
EULAR/ACR classification criteria.
Additional file 3: Figure S2 showing the prevalence of DCLO
impairment and autoantibody positivity in patients who did not
meet EULAR/ACR classification criteria.
Additional file 4: Figure S3 showing serum levels of ICTP, sE-
selectin, sIL2Raa and sE-selectin in patients who did not meet
EULAR/ACR classification criteria.
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